Chemclin Diagnostics Co. Ltd. A
Chemclin Diagnostics Co., Ltd. engages in the research and development, production, and sale of clinical immune chemiluminescence diagnostic reagents and instruments. Its products include LiCAA series of diagnostic reagents based on photo-induced chemiluminescence and CC series based on enzymatic chemiluminescence diagnostic reagents and instruments, primarily used for infectious diseases, such a… Read more
Chemclin Diagnostics Co. Ltd. A (688468) - Net Assets
Latest net assets as of September 2025: CN¥1.41 Billion CNY
Based on the latest financial reports, Chemclin Diagnostics Co. Ltd. A (688468) has net assets worth CN¥1.41 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.77 Billion) and total liabilities (CN¥363.17 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.41 Billion |
| % of Total Assets | 79.5% |
| Annual Growth Rate | 11.84% |
| 5-Year Change | 59.61% |
| 10-Year Change | N/A |
| Growth Volatility | 14.28 |
Chemclin Diagnostics Co. Ltd. A - Net Assets Trend (2017–2024)
This chart illustrates how Chemclin Diagnostics Co. Ltd. A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Chemclin Diagnostics Co. Ltd. A (2017–2024)
The table below shows the annual net assets of Chemclin Diagnostics Co. Ltd. A from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.42 Billion | +1.98% |
| 2023-12-31 | CN¥1.39 Billion | +0.60% |
| 2022-12-31 | CN¥1.38 Billion | +7.97% |
| 2021-12-31 | CN¥1.28 Billion | +44.10% |
| 2020-12-31 | CN¥887.36 Million | +2.35% |
| 2019-12-31 | CN¥866.97 Million | +11.81% |
| 2018-12-31 | CN¥775.38 Million | +19.83% |
| 2017-12-31 | CN¥647.08 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Chemclin Diagnostics Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 56002964174.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥445.54 Million | 31.46% |
| Common Stock | CN¥401.11 Million | 28.32% |
| Other Comprehensive Income | CN¥55.47 Million | 3.92% |
| Other Components | CN¥514.19 Million | 36.31% |
| Total Equity | CN¥1.42 Billion | 100.00% |
Chemclin Diagnostics Co. Ltd. A Competitors by Market Cap
The table below lists competitors of Chemclin Diagnostics Co. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Lydia Yesil Enerji Kaynaklari A.S.
IS:LYDYE
|
$234.49 Million |
|
Guilin Tourism Corp Ltd
SHE:000978
|
$234.55 Million |
|
Beijing Jiuzhou Yi Gui Environmental Technology Co. Ltd.
SHG:688485
|
$234.56 Million |
|
Zhang Xiaoquan Inc.
SHE:301055
|
$234.62 Million |
|
Xinjiang Tianshun Supply Chain Co Ltd
SHE:002800
|
$234.39 Million |
|
Shanghai Hile Bio-tech
SHG:603718
|
$234.31 Million |
|
Duni AB (publ)
PINK:DUNNF
|
$234.27 Million |
|
Talon Capital Corp. Class A Ordinary Shares
NASDAQ:TLNC
|
$234.19 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Chemclin Diagnostics Co. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,388,801,768 to 1,416,307,137, a change of 27,505,369 (2.0%).
- Net income of 127,074,717 contributed positively to equity growth.
- Dividend payments of 53,280,008 reduced retained earnings.
- Share repurchases of 51,091,168 reduced equity.
- Other comprehensive income increased equity by 55,468,462.
- Other factors decreased equity by 50,666,634.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥127.07 Million | +8.97% |
| Dividends Paid | CN¥53.28 Million | -3.76% |
| Share Repurchases | CN¥51.09 Million | -3.61% |
| Other Comprehensive Income | CN¥55.47 Million | +3.92% |
| Other Changes | CN¥-50.67 Million | -3.58% |
| Total Change | CN¥- | 1.98% |
Book Value vs Market Value Analysis
This analysis compares Chemclin Diagnostics Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.11x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.34x to 2.11x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CN¥3.22 | CN¥7.54 | x |
| 2018-12-31 | CN¥3.86 | CN¥7.54 | x |
| 2019-12-31 | CN¥2.16 | CN¥7.54 | x |
| 2020-12-31 | CN¥2.21 | CN¥7.54 | x |
| 2021-12-31 | CN¥3.19 | CN¥7.54 | x |
| 2022-12-31 | CN¥3.44 | CN¥7.54 | x |
| 2023-12-31 | CN¥3.49 | CN¥7.54 | x |
| 2024-12-31 | CN¥3.57 | CN¥7.54 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Chemclin Diagnostics Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.97%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 29.13%
- • Asset Turnover: 0.24x
- • Equity Multiplier: 1.29x
- Recent ROE (8.97%) is above the historical average (-6.35%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -67.26% | -136.61% | 0.45x | 1.10x | CN¥-499.94 Million |
| 2018 | -54.71% | -115.90% | 0.43x | 1.10x | CN¥-501.78 Million |
| 2019 | 16.22% | 30.92% | 0.46x | 1.15x | CN¥53.90 Million |
| 2020 | 13.19% | 27.98% | 0.42x | 1.13x | CN¥28.28 Million |
| 2021 | 11.16% | 30.32% | 0.33x | 1.12x | CN¥14.89 Million |
| 2022 | 11.06% | 32.80% | 0.29x | 1.15x | CN¥14.57 Million |
| 2023 | 10.61% | 33.09% | 0.24x | 1.31x | CN¥8.49 Million |
| 2024 | 8.97% | 29.13% | 0.24x | 1.29x | CN¥-14.56 Million |
Industry Comparison
This section compares Chemclin Diagnostics Co. Ltd. A's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $2,767,087,259
- Average return on equity (ROE) among peers: 6.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Chemclin Diagnostics Co. Ltd. A (688468) | CN¥1.41 Billion | -67.26% | 0.26x | $234.41 Million |
| Berry Genomics Co Ltd (000710) | $108.87 Million | -46.67% | 1.22x | $377.87 Million |
| Zhejiang DiAn Diagnostics Co (300244) | $9.50 Billion | 15.09% | 1.22x | $1.14 Billion |
| Beijing Strong Biotechnologies Inc (300406) | $1.70 Billion | 17.66% | 0.10x | $317.93 Million |
| Ningbo MedicalSystem Biotechnology Co Ltd (300439) | $308.32 Million | 33.58% | 0.53x | $283.14 Million |
| Maccura Biotechnology Co Ltd (300463) | $4.54 Billion | 21.06% | 0.45x | $576.46 Million |
| Guangdong Hybribio Biotech Co Ltd (300639) | $4.05 Billion | -16.18% | 0.14x | $319.65 Million |
| BGI Genomics Co Ltd (300676) | $4.25 Billion | 9.09% | 0.23x | $1.45 Billion |
| Amoy Diagnostics Co Ltd (300685) | $307.91 Million | 21.77% | 0.15x | $834.75 Million |
| Shanghai Labway Clinical Laboratory Co Ltd (301060) | $1.82 Billion | -6.01% | 0.44x | $226.85 Million |
| SMO ClinPlus Co. Ltd. (301257) | $1.08 Billion | 12.47% | 0.26x | $347.98 Million |